Rett syndrome (RTT) is a devastating neurodevelopmental disorder resulting from mutations in the X-linked gene encoding methyl-CpG-binding pro- tein 2 (MECP2). MECP2 mutations are also associated with other neurodevelop- mental diseases, including autism and schizophrenia. Therefore, elucidating the mechanism of RTT can contribute to understanding the pathogenesis of a wide range of neurodevelopmental diseases. Despite its importance, however, the RTT pathogenesis remains unclear, and effective therapeutic treatment has not been developed. Offering an opportunity to move toward this goal, however, is the recent advance in the stem cell research field of the development of induced pluripotent stem cell (iPSC) technology. This technology can yield important insights into dis- ease pathophysiology and has the potential to provide disease models for screening new drugs. Here, we discuss applications of recent stem cell technology to the field of research on RTT and describe the stem cell biology of RTT pathogenesis.
|Title of host publication||Stem Cell Genetics for Biomedical Research|
|Subtitle of host publication||Past, Present, and Future|
|Publisher||Springer International Publishing|
|Number of pages||15|
|Publication status||Published - Jun 27 2018|
All Science Journal Classification (ASJC) codes
- Biochemistry, Genetics and Molecular Biology(all)